These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28694232)

  • 1. Reinforcement of an antimicrobial stewardship task force aims at a better use of antibiotics of last resort: the COLITIFOS study.
    Davido B; Bouchand F; Dinh A; Perronne C; Villart M; Senard O; Salomon J
    Int J Antimicrob Agents; 2017 Aug; 50(2):142-147. PubMed ID: 28694232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration.
    Papadopoulos A; Ribera A; Mavrogenis AF; Rodriguez-Pardo D; Bonnet E; Salles MJ; Dolores Del Toro M; Nguyen S; Blanco-García A; Skaliczki G; Soriano A; Benito N; Petersdorf S; Pasticci MB; Tattevin P; Tufan ZK; Chan M; O'Connell N; Pantazis N; Kyprianou A; Pigrau C; Megaloikonomos PD; Senneville E; Ariza J; Papagelopoulos PJ; Giannitsioti E;
    Int J Antimicrob Agents; 2019 Mar; 53(3):294-301. PubMed ID: 30395988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosfomycin in antimicrobial stewardship programs.
    Múñez Rubio E; Ramos Martínez A; Fernández Cruz A
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):62-66. PubMed ID: 31131594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications.
    Sherry N; Howden B
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):289-306. PubMed ID: 29543500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased antimicrobial resistance and defined daily doses after implementation of a clinical culture-guided antimicrobial stewardship program in a local hospital.
    Wu CT; Chen CL; Lee HY; Chang CJ; Liu PY; Li CY; Liu MY; Liu CH
    J Microbiol Immunol Infect; 2017 Dec; 50(6):846-856. PubMed ID: 26809591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon.
    Ballouz T; Zeenny RM; Haddad N; Rizk N; Kanj SS
    J Infect Dev Ctries; 2021 Sep; 15(9):1308-1313. PubMed ID: 34669601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?
    Ozsurekci Y; Aykac K; Cengiz AB; Bayhan C; Sancak B; Karadag Oncel E; Kara A; Ceyhan M
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):233-8. PubMed ID: 27041107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J; Tang YQ; Sun JY
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.
    Zaidi ST; Al Omran S; Al Aithan AS; Al Sultan M
    J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement.
    ; Guan X; He L; Hu B; Hu J; Huang X; Lai G; Li Y; Liu Y; Ni Y; Qiu H; Shao Z; Shi Y; Wang M; Wang R; Wu D; Xie C; Xu Y; Yang F; Yu K; Yu Y; Zhang J; Zhuo C
    Clin Microbiol Infect; 2016 Mar; 22 Suppl 1():S15-25. PubMed ID: 26627340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the hidden potential of fosfomycin for the fight against severe Gram-negative infections.
    Saiprasad PV; Krishnaprasad K
    Indian J Med Microbiol; 2016; 34(4):416-420. PubMed ID: 27934817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
    Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
    Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study on the effects of colistin therapy in children with multidrug-resistant Gram-negative bacterial pathogens: impact of HIV status on outcome.
    Dimitriades K; Morrow BM; Jeena P
    Arch Dis Child; 2014 Mar; 99(3):262-6. PubMed ID: 24170687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.